BioCentury | Jun 14, 2004
Emerging Company Profile

Concurrent: The jump from computing

...was part of a joint venture with Ligand Pharmaceuticals Inc. (LGND, San Diego, Calif.) called Allergan Ligand Retinoid Therapeutics Inc....
BioCentury | Mar 16, 1998
Company News

Allergan Specialty board of directors update

...president and CEO of Crescendo Pharmaceuticals Corp. ; Marvin Rosenthale, formerly president and CEO of Allergan Ligand Retinoid Therapeutics Inc....
BioCentury | Dec 8, 1997
Company News

Allergan Ligand, Ligand, Allergan deal

...also completed its purchase of a half-interest in ALRI's assets for $8.9 million in cash. Allergan Ligand Retinoid Therapeutics Inc....
BioCentury | Sep 29, 1997
Company News

Allergan Ligand Retinoid Therapeutics Inc, Ligand Pharmaceuticals Inc, Allergan Inc deal

...lottery system. After the buyback is completed LGND and Allergan will have no ongoing collaborations. Allergan Ligand...
BioCentury | Sep 29, 1997
Finance

Raab promises blockbuster IPO

...week to $16.25 after the company and partner Allergan exercised their option to buy back Allergan Ligand...
BioCentury | Sep 8, 1997
Clinical News

Oral Panretin 9-cis-retinoic acid data

...San Diego, Calif.) conducted the trial on behalf of ALRI. Phase III testing has begun. Allergan Ligand Retinoid Therapeutics Inc....
BioCentury | Sep 2, 1997
Finance

When lightning strikes

...of Microcide (MCDE). The infectious disease company closed the week at $12. EBB & FLOW: Allergan Ligand...
...school lunch program by its former Andrew & Williamson Sales Co. subsidiary. EBB & FLOW: Allergan Ligand...
BioCentury | Sep 2, 1997
Clinical News

Panretin 9-cis-retinoic acid topical gel data

...submissions for marketing approval in the U.S. and Europe in late 1997 or early 1998. Allergan Ligand Retinoid Therapeutics Inc....
BioCentury | Jul 14, 1997
Clinical News

Oral Panretin 9-cis-retinoic acid: Phase II Update

...testing for the topical form of the drug will be unblinded in the fourth quarter. Allergan Ligand Retinoid Therapeutics Inc....
BioCentury | Jul 14, 1997
Clinical News

Oral Panretin 9-cis-retinoic acid: Phase II Update

Allergan Ligand Retinoid Therapeutics Inc. (ALRI), San Diego, Calif. Product: Oral Panretin 9-cis-retinoic acid Indication: Treat psoriasis Status: Phase II testing is continuing in a dose-response study. Effectiveness has been demonstrated in patients with moderate...
Items per page:
1 - 10 of 33
BioCentury | Jun 14, 2004
Emerging Company Profile

Concurrent: The jump from computing

...was part of a joint venture with Ligand Pharmaceuticals Inc. (LGND, San Diego, Calif.) called Allergan Ligand Retinoid Therapeutics Inc....
BioCentury | Mar 16, 1998
Company News

Allergan Specialty board of directors update

...president and CEO of Crescendo Pharmaceuticals Corp. ; Marvin Rosenthale, formerly president and CEO of Allergan Ligand Retinoid Therapeutics Inc....
BioCentury | Dec 8, 1997
Company News

Allergan Ligand, Ligand, Allergan deal

...also completed its purchase of a half-interest in ALRI's assets for $8.9 million in cash. Allergan Ligand Retinoid Therapeutics Inc....
BioCentury | Sep 29, 1997
Company News

Allergan Ligand Retinoid Therapeutics Inc, Ligand Pharmaceuticals Inc, Allergan Inc deal

...lottery system. After the buyback is completed LGND and Allergan will have no ongoing collaborations. Allergan Ligand...
BioCentury | Sep 29, 1997
Finance

Raab promises blockbuster IPO

...week to $16.25 after the company and partner Allergan exercised their option to buy back Allergan Ligand...
BioCentury | Sep 8, 1997
Clinical News

Oral Panretin 9-cis-retinoic acid data

...San Diego, Calif.) conducted the trial on behalf of ALRI. Phase III testing has begun. Allergan Ligand Retinoid Therapeutics Inc....
BioCentury | Sep 2, 1997
Finance

When lightning strikes

...of Microcide (MCDE). The infectious disease company closed the week at $12. EBB & FLOW: Allergan Ligand...
...school lunch program by its former Andrew & Williamson Sales Co. subsidiary. EBB & FLOW: Allergan Ligand...
BioCentury | Sep 2, 1997
Clinical News

Panretin 9-cis-retinoic acid topical gel data

...submissions for marketing approval in the U.S. and Europe in late 1997 or early 1998. Allergan Ligand Retinoid Therapeutics Inc....
BioCentury | Jul 14, 1997
Clinical News

Oral Panretin 9-cis-retinoic acid: Phase II Update

...testing for the topical form of the drug will be unblinded in the fourth quarter. Allergan Ligand Retinoid Therapeutics Inc....
BioCentury | Jul 14, 1997
Clinical News

Oral Panretin 9-cis-retinoic acid: Phase II Update

Allergan Ligand Retinoid Therapeutics Inc. (ALRI), San Diego, Calif. Product: Oral Panretin 9-cis-retinoic acid Indication: Treat psoriasis Status: Phase II testing is continuing in a dose-response study. Effectiveness has been demonstrated in patients with moderate...
Items per page:
1 - 10 of 33